NY-ADACORE
13.6.2024 11:23:28 CEST | Business Wire | Press release
AdaCore https://www.adacore.com/ is thrilled to be part of the Safety-Critical Rust Consortium alongside The Rust Foundation, Arm, Ferrous Systems, OxidOS, Synopsys, HighTec EDV-Systeme GmbH, TrustInSoft, Veecle, and Woven by Toyota. The primary objective of this group will be to support the responsible use of the Rust programming language in safety-critical software — systems whose failure can impact human life or cause severe environmental or property harm.
Safety-Critical Rust Consortium Membership is open to Rust Foundation member organizations and other invitees, such as industry, academic, and legal experts.
Work under the consortium will begin with the creation of a public charter and goals, and meeting minutes will be published on an ongoing basis. The Safety-Critical Rust Consortium will liaise with the Rust Project through Rust Foundation Project Directors and members of Rust Project teams. The Consortium’s scope, which will be fully delineated in the charter, may include the development of guidelines, linters, libraries, static analysis tools, formal methods, and language subsets to meet industrial and legal requirements. The Consortium’s deliverables will be developed and licensed in a manner compatible with other Rust Project endeavors.
The group may further shepherd Rust Foundation-funded implementation work, including grants to existing academic teams or FOSS projects. Any Rust Foundation-funded work will be submitted upstream, licensed as FOSS, and any specifications will be freely available. The group will further attempt to coordinate with and expand on existing safety-critical projects and standards including SAE JA1020.
Programming-language safety refers to a language’s ability to prevent errors or undefined behaviors at compile time or runtime. On the other hand, "safety-critical" refers to a system’s ability to operate without causing accidents or catastrophic failures that will result in harm to people, property or the environment. So, while safety-critical systems rely on languages that emphasize safety and security, such as Rust, programming tools are only one component of the overall strategy.
Tony Aiello is the Product Manager at AdaCore,
“At AdaCore, we focus on industries where safety, security, and reliability are paramount including automotive, aviation, and space. AdaCore has decades of experience serving these industries with Ada, SPARK, and C++. Participating in the Safety-Critical Rust Consortium enables us to leverage our expertise to help the Rust community best position itself to serve the safety-critical community’s needs.”
About AdaCore
Everything we do at AdaCore is centered around helping developers build safe, secure and reliable software. With over 30 years of experience working with the most respected companies in industries such as aerospace, defense and railways, we build tools and provide services that ease the complex and often difficult process of developing high-integrity software. As the need for truly secure and reliable applications expands into industries such as automotive, medical, energy, and IoT, we’re excited to bring our time-tested technologies, expertise and services to help a whole new generation of developers.
About The Rust Foundation
The Rust Foundation is an independent nonprofit dedicated to the safety, security, sustainability, and health of the Rust Programming language and the people who use it. Through close partnerships with organizations passionate about Rust and the growing Rust Project and community, the Rust Foundation is helping forge a better open-source future with Rust.
Visit the Rust Foundation website to learn more. Follow the Rust Foundation on X (formerly known as Twitter) and on LinkedIn.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240613424332/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Announces U.S. FDA Acceptance of RelabotulinumtoxinA Biologics License Application Resubmission2.2.2026 07:00:00 CET | Press release
The United States (U.S.) Food and Drug Administration (FDA) has accepted the Biologics License Application (BLA) resubmission for RelabotulinumtoxinA for the temporary improvement of moderate-to-severe glabellar lines (frown lines) and lateral canthal lines (crow’s feet) in adults RelabotulinumtoxinA is designed to optimize molecule integrity to deliver fast onset of action as early as Day 1 and sustained results for six months for frown lines and crow’s feet and has been approved in over 20 markets, including in the European Union1-3 Galderma (SIX: GALD) today announced that the U.S. FDA has accepted the BLA resubmission for RelabotulinumtoxinA for the temporary improvement of moderate-to-severe glabellar lines (frown lines) and lateral canthal lines (crow’s feet) in adults. Galderma has worked closely with the U.S. FDA to implement adjustments to its manufacturing process. Galderma is committed to using its expertise and heritage in the neuromodulator space to develop next-generation
High-end Aesthetic Brand ‘Lorient’ Gains Global Prestige at IMCAS 20261.2.2026 08:00:00 CET | Press release
Lorient, a premium aesthetic brand, announced that it has drawn global attention at the 27th IMCAS World Congress 2026 in Paris, attracting over 15,000 professionals and demonstrating its leadership in aesthetic innovation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260131322203/en/ Lorient’s low degree of modification delivers a smooth injection experience and high biocompatibility (Image: Lorient) The highlight was a session led by Dr. Jani van Loghem, a globally revered key opinion leader known for establishing international aesthetic safety protocols. His involvement provided a prestigious validation of the technical excellence of Lorient. Alongside him, prominent Korean medical experts Dr. Won Lee and Dr. Do Young Rhee shared clinical insights that drew widespread praise from the international medical community. Central to the academic discussions was Lorient’s "safety-first" philosophy for its premium HA filler ran
Sharjah Ruler Receives Portugal’s Grand Collar of Order of Camões31.1.2026 18:27:00 CET | Press release
His Excellency Marcelo Rebelo de Sousa, President of the Portuguese Republic, awarded His Highness Sheikh Dr Sultan bin Mohammed Al Qasimi, Supreme Council Member and Ruler of Sharjah, the Grand Collar of the Order of Camões (Grande Colar da Ordem de Camões), the highest sovereign cultural order in Portugal. His Highness is the first Arab figure to receive the Order of Camões and the sixth recipient worldwide. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260131119526/en/ Sharjah Ruler receives Portugal’s Grand Collar of Order of Camões (Photo: AETOSWire) The honour was conferred during a ceremony hosted by the Portuguese President at the Presidential Palace in Lisbon. The event was attended by Sheikha Bodour bint Sultan Al Qasimi, Chairperson of the Sharjah Book Authority, alongside senior officials. The ceremony recognised His Highness’s prominent global stature, as a leading figure in culture, intellectual thought and in
Incyte Announces Positive CHMP Opinion for Zynyz® (retifanlimab) for First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC)30.1.2026 15:29:00 CET | Press release
Pending the European Commission decision, Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) will be the first PD-1 immunotherapy treatment for patients with advanced squamous cell carcinoma of the anal canal (SCAC) in EuropeGlobally, the prevalence of SCAC is estimated at around 1 or 2 cases per 100,000 people, with a higher incidence in women than in men1,2,3The Committee for Medicinal Products for Human Use (CHMP) positive opinion is based on data from the Phase 3 POD1UM-303/InterAACT2 trial which showed patients with advanced SCAC achieved significantly improved progression-free survival with Zynyz in combination with carboplatin and paclitaxel as a first-line treatment4 Incyte (Nasdaq:INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (
Mediawan to Acquire The North Road Company, Creating a New Global Independent Content Platform30.1.2026 13:32:00 CET | Press release
Mediawan, the leading independent European studio led by Pierre-Antoine Capton, co-founded by Capton, Xavier Niel and Matthieu Pigasse, today announced the signing of an agreement to acquire The North Road Company (“North Road”), the preeminent independent U.S.-based studio founded by Peter Chernin. The combination creates one of the world’s largest independent studios with major creative hubs in the five continents and capabilities spanning all genres, formats and audiences. Together, Mediawan and North Road will have a stronger ability to accelerate the development of powerful IP, foster fresh creative synergies through format adaptations and co-production opportunities, and deliver ever greater value to viewers, talent and partners worldwide. The acquisition brings together two of the most dynamic independent studios in the sector with world-class creative talent, premium IP, and the scale to deliver content at the highest level. In an industry undergoing significant consolidation,
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
